Top

Published in:

01-04-2016 | Research

Associations of Polymorphisms in mir-196a2, mir-146a and mir-149 with Colorectal Cancer Risk: A Meta-Analysis

Authors: Liping Xu, Wenru Tang

Published in: Pathology & Oncology Research | Issue 2/2016

Abstract

MicroRNAs (miRNAs) are non-coding RNAs which act as tumor suppressors or oncogenes. And single nucleotide polymorphism (SNP) in miRNA regions is one type of genetic variations in human genome. Various studies have investigated the associations of miRNAs SNP and kinds of cancers. In this article, we searched eligible studies to explore the relationships between mir-196a2 /mir-146a /mir-149 polymorphisms and colorectal cancer (CRC). A literature search of PubMed, Web of Science and ScienceDirect was conducted to identify all relevant studies. Three genetic models with pooled ratio and 95 % confidence interval were used to evaluate the associations. We found that mir-196a2 polymorphism was significantly associated with CRC in Asian group (additive model: OR = 1.197, 95 %CI 1.084 ~ 1.32, P < 0.001; dominant model: OR = 1.247, 95 %CI 1.065 ~ 1.46, P = 0.006; recessive model: OR = 1.298, 95 %CI 1.101 ~ 1.531, P = 0.002). And no associations were observed between SNPs of mir-146a, mir-149 and CRC in three genetic models. We also found CRC risk was not associated with mir-146a and mir-149 polymorphisms in population subgroup analysis. The current meta-analysis suggests that mir-196a2 polymorphism is associated with CRC, especially in Asian group. While, no associations have been found between mir-146a /mir-149 polymorphisms and CRC.

Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355CrossRefPubMed

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297CrossRefPubMed

Bartels CL, Tsongalis GJ (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55:623–631CrossRefPubMed

Rosenfeld N, Aharonov R, Meiri E et al (2008) MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26:462–469CrossRefPubMed

Bentwich I (2005) Prediction and validation of microRNAs and their targets. FEBS Lett 579:5904–5910CrossRefPubMed

Brennecke J, Stark A, Russell RB et al (2005) Principles of microRNA-target recognition. PLoS Biol 3:e85CrossRefPubMedPubMedCentral

Yang W, Chendrimada TP, Wang Q et al (2006) Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 13:13–21CrossRefPubMedPubMedCentral

Wu M, Jolicoeur N, Li Z et al (2008) Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 29:1710–1716CrossRefPubMed

Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed

10.

Yang L, Parkin DM, Li L et al (2003) Time trends in cancer mortality in China: 1987–1999. Int J Cancer 106:771–783CrossRefPubMed

11.

Center MM, Jemal A, Ward E (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18:1688–1694CrossRefPubMed

12.

Zhan JF, Chen LH, Chen ZX et al (2011) A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch Med Res 42:144–148CrossRefPubMed

13.

Tian T, Shu Y, Chen J et al (2009) A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 18:1183–1187CrossRefPubMed

14.

Kim MJ, Yoo SS, Choi YY et al (2010) A functional polymorphism in the pre-microRNA-196a2 and the risk of lung cancer in a Korean population. Lung Cancer 69:127–129CrossRefPubMed

15.

Hu Z, Liang J, Wang Z et al (2009) Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat 30:79–84CrossRefPubMed

16.

Hoffman AE, Zheng T, Yi C et al (2009) microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res 69:5970–5977CrossRefPubMedPubMedCentral

17.

Qi P, Dou TH, Geng L et al (2010) Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum Immunol 71:621–626CrossRefPubMed

18.

Egger M, Davey SG, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634CrossRefPubMedPubMedCentral

19.

Chen H, Sun LY, Chen LL et al (2012) A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Intern Med J 42:e115–e119CrossRefPubMed

20.

Min KT, Kim JW, Jeon YJ et al (2012) Association of the miR-146aC > G, 149C > T, 196a2C > T, and 499A > G polymorphisms with colorectal cancer in the Korean population. Mol Carcinog 51(Suppl 1):E65–E73CrossRefPubMed

21.

Zhu L, Chu H, Gu D et al (2012) A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol 31:350–354CrossRefPubMed

22.

Hezova R, Kovarikova A, Bienertova-Vasku J et al (2012) Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol 18:2827–2831CrossRefPubMedPubMedCentral

23.

Vinci S, Gelmini S, Mancini I et al (2013) Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods 59:138–146CrossRefPubMed

24.

Zhang MW, Jin MJ, Yu YX et al (2012) Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk. Mol Carcinog 51(Suppl 1):E21–E31PubMed

25.

Lv M, Dong W, Li L et al (2013) Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population. J Cancer Res Clin Oncol 139:1405–1410CrossRefPubMed

26.

Chae YS, Kim JG, Lee SJ et al (2013) A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res 33:3233–3239PubMed

27.

Ma L, Zhu L, Gu D et al (2013) A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch Toxicol 87:825–833CrossRefPubMed

28.

Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10:789–799CrossRefPubMed

29.

Mueller DW, Bosserhoff AK (2011) MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer 129:1064–1074CrossRefPubMed

30.

Liu XH, Lu KH, Wang KM et al (2012) MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer 12:348CrossRefPubMedPubMedCentral

31.

Yuan Z, Zeng X, Yang D et al (2013) Effects of common polymorphism rs11614913 in Hsa-miR-196a2 on lung cancer risk. PLoS One 8:e61047CrossRefPubMedPubMedCentral

32.

Xu J, Hu Z, Xu Z et al (2009) Functional variant in microRNA-196a2 contributes to the susceptibility of congenital heart disease in a Chinese population. Hum Mutat 30:1231–1236CrossRefPubMed

33.

Hu Z, Chen J, Tian T et al (2008) Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 118:2600–2608CrossRefPubMedPubMedCentral

34.

Wei J, Zheng L, Liu S et al (2013) MiR-196a2 rs11614913 T > C polymorphism and risk of esophageal cancer in a Chinese population. Hum Immunol 74:1199–1205CrossRefPubMed

35.

Wang S, Tao G, Wu D et al (2013) A functional polymorphism in MIR196A2 is associated with risk and prognosis of gastric cancer. Mol Carcinog 52(Suppl 1):E87–E95CrossRefPubMed

36.

Zhang H, Su YL, Yu H et al (2012) Meta-analysis of the association between Mir-196a-2 polymorphism and cancer susceptibility. Cancer Biol Med 9:63–72PubMedPubMedCentral

37.

Li YJ, Zhang ZY, Mao YY et al (2014) A genetic variant in MiR-146a modifies digestive system cancer risk: a meta-analysis. Asian Pac J Cancer Prev 15:145–150CrossRefPubMed

38.

Taganov KD, Boldin MP, Chang KJ et al (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103:12481–12486CrossRefPubMedPubMedCentral

39.

Pastrello C, Polesel J, Della PL et al (2010) Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis 31:2124–2126CrossRefPubMed

40.

Wang PY, Gao ZH, Jiang ZH et al (2013) The associations of single nucleotide polymorphisms in miR-146a, miR-196a and miR-499 with breast cancer susceptibility. PLoS One 8:e70656CrossRefPubMedPubMedCentral

41.

Zhou B, Dong LP, Jing XY et al (2014) Association between miR-146aG > C and miR-196a2C > T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. Biol, Tumour

42.

Lin RJ, Lin YC, Yu AL (2010) miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog 49:719–727PubMed

43.

Oster B, Linnet L, Christensen LL et al (2013) Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. Int J Cancer 132:2303–2315CrossRefPubMed

44.

Zhang J, Liu YF, Gan Y (2012) Lack of association between miR-149 C > T polymorphism and cancer susceptibility: a meta-analysis based on 4,677 cases and 4,830 controls. Mol Biol Rep 39:8749–8753CrossRefPubMed

45.

Zhang YG, Shi JX, Song CH et al (2013) Association of mir-499 and mir-149 polymorphisms with cancer risk in the Chinese population: evidence from published studies. Asian Pac J Cancer Prev 14:2337–2342CrossRefPubMed

Title: Associations of Polymorphisms in mir-196a2, mir-146a and mir-149 with Colorectal Cancer Risk: A Meta-Analysis
Authors: Liping Xu
Wenru Tang
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9843-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer

Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions

L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells

Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001–2013 – A Single Centre Experience

Erratum to: Menthol Inhibits the Proliferation and Motility of Prostate Cancer DU145 Cells

Chemokine Expression Profiles of Human Hepatoma Cell Lines Mediated by Hepatitis B Virus X Protein

Keynote webinar | Spotlight on antibody–drug conjugates in cancer